#CDNA

CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results CareDx, Inc.— The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑ value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025..

2 months ago

#CDNA CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/CDNA/care-dx-announ...

0 0 0 0

InsiderFinance

@insiderfinance.com

2 months ago

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RKLB, #CCCX, #WDC, #XOM, #CDNA

#OptionFlow #OptionsTrading #Trading

0 0 0 0

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response CareDx (Nasdaq: CDNA) and 10x Genomics (Nasdaq: TXG) launched ImmuneScape, a multiomics research program to map immune biology in transplant rejection and therapeutic response.The collaboration will use 10x Xenium spatial and Chromium Flex single cell platforms to profile FFPE biopsy samples at cellular resolution, focusing on antibody-mediated rejection (AMR) and microvascular inflammation (MVI). Insights are intended to support future diagnostic development and to correlate tissue-level immune architecture with clinical outcomes, including response to anti-CD38 therapies.

2 months ago

#TXG #CDNA CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

www.stocktitan.net/news/TXG/care-dx-and-10x...

0 0 0 0

RNAConnect

@rnaconnect.bsky.social

2 months ago

Read the latest RNAConnect publication titled Improved long-transcript representation in Oxford Nanopore direct RNA sequencing with UltraMarathonRT

Ditch the doomscrolling and read the latest data showing how uMRT can improve your ONT direct RNA-Seq.

Highlights:
• Notable gains for >5 kb
• ↑ NIC & NNIC + ↑ intron retention
• +~25% higher cDNA yield

Dive into the data → www.biorxiv.org/content/10.6...

#RNA #RNAseq #DRS #cDNA #RNASky

2 1 0 0

Australasian College for Infection Prevention and Control

3 months ago

#CDNA SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

www.stocktitan.net/news/CDNA/shore-study-de...

0 0 0 0

@acipc.bsky.social

3 months ago

HICSIG Update at #ACIPC25

A/Prof Kate McCarthy & Dr Megan Young delivered an important update on measles exposure in healthcare settings& and what’s new in the latest CDNA guidelines.

A practical & timely session as measles risks continue to rise.

#ACIPC25 #IPC #Measles #CDNA

1 0 0 0

4 months ago

#CDNA CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

www.stocktitan.net/news/CDNA/care-dx-announ...

0 0 0 0

RNAConnect

@rnaconnect.bsky.social

4 months ago

[1/2] A new publication from Warkentin & Pyle presents a practical workflow for accurate circRNA detection using UltraMarathonRT® (uMRT), a highly processive reverse transcriptase.

Pub 🔗 in the comments.

#cDNA #RNA #RNAseq #circRNA #RTPCR #RNASky

1 0 2 0

RNAConnect

@rnaconnect.bsky.social

4 months ago

We’re excited to (RNA)Connect with you at #ASHG25!

Visit Booth #121 to discover how uMRT reveals more from every RNA sample.

▪️ 10–30% more genes detected
▪️ Superior quantification of long transcripts

See what your #RNASeq data has been missing.

#RNA #cDNA #RNASky #transcriptomics #genomics

1 0 0 0

CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting CareDx, Inc.– The Transplant Company™– a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers– today announced new innovations and products that will be featured at The American Society for...

5 months ago

#CDNA CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting

www.stocktitan.net/news/CDNA/care-dx-announ...

0 0 0 0

Medicare Coverage Decision: CareDx Files Response on Critical Transplant Testing Policy Draft Transplant diagnostics leader CareDx submits formal response to Medicare's draft Local Coverage Determination for molecular transplant rejection testing. Public comment period ended August 31.

6 months ago

#CDNA CareDx Issues Comment Letter on Draft LCD Policy

www.stocktitan.net/news/CDNA/care-dx-issues...

0 0 0 0

CareDx Reports Record 49,500 Tests in Q2: AlloSure Kidney Growth Hits 20% While Company Narrows Revenue Guidance CareDx achieves 13% testing volume growth, maintains $367-373M revenue outlook. Discover Q2 performance metrics and AlloSure's market expansion. See full results.

7 months ago

#CDNA CareDx Announces Second Quarter 2025 Financial Results

www.stocktitan.net/news/CDNA/care-dx-announ...

0 0 0 0

CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation CareDx (NASDAQ: CDNA) has published its landmark Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation, demonstrating the clinical utility of its AlloSure® donor-derived cell-free DNA (dd-cfDNA) test in kidney transplant surveillance.The extensive study, involving 1,743 patients across 56 U.S. transplant centers and 18,584 AlloSure tests, revealed that elevated AlloSure was associated with a 6-fold increase in rejection detection in surveillance biopsies and a 4-fold increase in for-cause biopsies. The test can detect rejection up to four months before antibody-mediated rejection (ABMR) and one month before T-cell mediated rejection (TCMR), positioning it as a powerful early detection tool in kidney transplantation.

7 months ago

#CDNA CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation

www.stocktitan.net/news/CDNA/care-dx-announ...

0 0 0 0

CareDx Revolutionizes Transplant Care: New AI Platform Achieves 816% Higher Accuracy in Organ Rejection Detection Breakthrough AI diagnostic platform validated across 4,100+ transplant biopsies shows unprecedented accuracy in organ rejection detection. See clinical results.

7 months ago

#CDNA CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress

www.stocktitan.net/news/CDNA/care-dx-announ...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

7 months ago

Small-cap stocks oversold with improving relative strength, Tue Jul 22nd - #FVRR #CDNA #JXG - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection CareDx (NASDAQ:CDNA) announced a proposed draft Local Coverage Determination (LCD) that maintains coverage for surveillance testing in solid organ transplant rejection detection. The draft LCD, open for comments until August 31, 2025, continues to provide coverage for kidney, heart, and lung transplant surveillance testing without requiring protocol biopsy.The policy introduces a bundled payment concept for surveillance testing. CareDx will provide additional information during its earnings call on August 6, 2025. The company's CEO, John W. Hanna, emphasized that this draft policy reinforces coverage for surveillance testing and supports their position on improving transplant patient outcomes.

7 months ago

#CDNA CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection

www.stocktitan.net/news/CDNA/care-dx-announ...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

7 months ago

Small-cap stocks with strong volume declines, Thu Jul 17th - #NEXM #CEPO #PDSB #NB #KLRS #GAME #CDNA #BCLI #OPAD #EB - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

GENEWIZ from Azenta Life Sciences

@genewiz.bsky.social

9 months ago

How to Improve Your RNA-Seq Data with UMIs and ERCC RNA Scientists have developed two powerful tools for RNA sequencing (RNA-Seq) experiments to minimize bias and variability: unique molecular identifiers (UMIs) and ERCC RNA spike-ins. We’ll cover the basi...

What are #UMIs?

UMIs are short, random #nucleotide sequences added to individual #transcripts during library preparation and uniquely identify #cDNA. Learn how this powerful tool cleans up #RNASeq data for #GeneExpression analysis, resulting in improved #RNA-Seq data.

Read now: hubs.ly/Q03nSq1g0

0 1 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks with improving money flow, Wed Jun 4th - #AEHR #CDNA #DSGN #INDI #LVLU #MCHX #NAAS #PLAY #SSSS #TCRX #XBIT #YEXT #XPOF #PL #NOAH #MLNK #KYN #GSL #DHT #CHPT #ADNT #WULF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

CareDx Doubles Down on Share Buybacks: $50M Complete, Fresh $50M Program Launches Amid 18% Growth CareDx repurchases 5% of shares while posting 18% revenue growth. New $50M buyback program authorized as company maintains $231M cash position. See growth strategy.

9 months ago

#CDNA CareDx Announces Repurchase of 5% of Outstanding Shares

www.stocktitan.net/news/CDNA/care-dx-announ...

0 0 0 0

@thewesternproducer.bsky.social

9 months ago

Customer diversity seen as benefit to exporters | The Western Producer Exporting products to the United States is beneficial for Canadian businesses, but selling to multiple countries will often makea company more productive and competitive

Sixty-six per cent of Canadian exporters rely solely on United States, but economists say that can be hard on the bottom line vist.ly/3n5n8q3 #CdnA

0 0 0 0

Libby Snell

@libbysnell.bsky.social

9 months ago

The sun is finally out in San Diego!! @rnasociety.bsky.social #RNA25 If you missed @nanoporetech.com 's sponsored session presentation on Wed w/ all our updates don't worry! We have 2 posters up tonight (Fri). P2-285 for #cDNA and P2-331 for #directRNA. Come speak to us at the booth, too! #RNA2025

5 1 0 0

Libby Snell

@libbysnell.bsky.social

9 months ago

Oxford Nanopore at the RNA Society 2025 Meeting Join the Oxford Nanopore Technologies team at our sponsor seminar or at our booth at the RNA Society 2025 Meeting!

Hello @rnasociety.bsky.social ! Happy to be in San Diego for this year's #RNA25 mtg! Join us at @nanoporetech.com 's session tomorrow (Wed 1:10 pm) to hear updates on #directRNA & #cDNA sequencing. Lunch provided! Reg below. Or chat to us at booth 5! #RNA2025
nanoporetech.com/about/events...

8 2 0 0

Libby Snell

@libbysnell.bsky.social

9 months ago

Oxford Nanopore at the RNA Society 2025 Meeting Join the Oxford Nanopore Technologies team at our sponsor seminar or at our booth at the RNA Society 2025 Meeting!

#RNA25 don't miss Oxford Nanopore's 1:10 pm session tomorrow w/amazing speakers: Leland Taylor (NIH/NHGRI) using #directRNA seq studying disease and Yasuhiro Murakawa (Kyoto Univ) using #cDNA & #dRNA investigating human transcripomes. Lunch provided #RNA2025
nanoporetech.com/about/events...

1 0 0 0